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Abstract
Background: The recently identified phenomenon of double-stranded RNA (dsRNA)-mediated gene activation
(RNAa) has been studied extensively, as it is present in humans, mice, and Caenorhabditis elegans, suggesting that
dsRNA-mediated RNAa is an evolutionarily conserved mechanism. Previous studies have shown that dsP21-322 can
induce tumor suppressor gene p21 expression in several human cancer cells. Nonetheless, the role of dsRNAs in the
activation of gene expression, including their target molecules and associated key factors, remains poorly understood.
Methods: Oligonucleotides were used to overexpress dsRNAs and dsControl. Real-time PCR and Western blotting were
used to detect corresponding mRNA and protein expression, respectively. Fluorescence microscopy was used to
examine the kinetics of dsRNA subcellular distribution. Luciferase reporter assays were performed to verify dsRNA target
molecules. Chromatin immunoprecipitation (ChIP) assays were carried out to determine whether histone modification
and other associated key factors are involved in saRNA-mediated p21 expression.
Results: We demonstrated that dsRNA-mediated p21 induction in human cell lines is a common phenomenon. This
process occurs at the transcriptional level, and the complementary p21 promoter is the intended dsRNA target.
Additionally, ChIP assays indicated that p21 activation was accompanied by an increased enrichment of AGO1 and the
trimethylation of histone H3K4 at dsRNA-targeted genomic sites.
Conclusion: These data systematically reveal the mechanistic and functional aspects of ncRNA-mediated p21
activation in human cancer cells, which may be a useful tool to analyze gene function and aid in the development of
novel drug targets for cancer therapeutics.
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Background
In recent years, the regulation of gene expression by non-
coding RNAs (ncRNAs) has become recognized as an
evolutionarily conserved mechanism in biology. The well-
studied smaller ncRNAs, such as short interfering RNAs
(siRNAs) and microRNAs, can posttranscriptionally and
epigenetically silence gene expression [1–4]. Many long
ncRNAs, such as Xist and Air, have also been studied ex-
tensively in gene silencing, revealing epigenetic mechanisms
[5, 6]. RNA interference (RNAi)-based gene silencing ap-
proaches have been performed in humans, and ongoing
clinical trials show promise for treating cancer or providing
alternatives to traditional small molecule therapies [7, 8].
Similar to double-stranded RNAs (dsRNAs), ncRNAs
have more recently also been shown to induce gene
expression by a phenomenon referred to as saRNA
activation (RNAa) [9–18]; these types of dsRNAs are
referred to as small activating RNAs (saRNAs). Several
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models of RNAa have been described, including the acti-
vation of transcription through complementary binding to
target sequences within gene promoters and/or overlap-
ping noncoding transcripts [19–23]. RNAa also offers an
approach for gene regulation and represents a new
strategy to stimulate gene expression. Although much
is known regarding the mechanisms of gene silencing
by small dsRNAs in human cells, little is known about
the mechanism of RNA-induced gene activation.
p21Waf1/Cip1 (p21) [CDKN1A (cyclin-dependent kinase
inhibitor 1A)] is a well-characterized cyclin-dependent
kinase inhibitor that belongs to the Cip/Kip family of
cyclin-dependent kinase inhibitors and is a key mediator
of several cellular processes including cell death, DNA
repair, senescence and aging [24, 25]. Transcriptional
regulation is mediated by multiple transcription factors
(p53, Sp1/Sp3 and c-Myc) and plays a critical role in the
expression and activity of p21 [26]. p21 is a potent tumor
suppressor gene (TSG) in cancer cells, although loss-of-
function mutations in p21 are generally a rare occurrence
[27]. Therefore, p21 is an ideal target for RNAa-mediated
inhibition of tumor cell growth.
Previous studies have shown that a small activating
RNA could markedly induce p21 expression by targeting
the p21 gene promoter region in cancer cells, resulting
in cell-cycle arrest and apoptosis in vitro [10, 28]. Recent
observations also demonstrated that the intravesical de-
livery of saRNAs inhibited orthotopic bladder or xeno-
graft prostate tumor growth by inducing p21 expression
[29, 30]. Our group further demonstrated that saRNAs
associated specifically with their intended target on the
p21 promoter and interacted with the heterogeneous
nuclear ribonucleoproteins A2/B1(hnRNPA2/B1) to medi-
ate p21 induction [19]. However, the limited anecdotal
evidence that is currently available makes it difficult to
understand the molecular mechanisms of RNAa. In this
study, we performed a detailed RNAa analysis using
saRNAs and examined the kinetics of the saRNA sub-
cellular distribution and the rate of p21 gene induction.
We also showed that the upregulation of p21 expres-
sion by saRNAs occurs at the transcriptional level and
is associated with activating epigenetic markers and argo-
naute 1 (AGO1) binding to saRNA-targeted genomic sites.
These findings reveal functional and mechanistic aspects
of RNAa that will help inform in vivo applications in
medicine and aid in the development of RNAa as a
laboratory tool.
Methods
dsRNA design and synthesis
A 21-nucleotide dsRNA targeting the p21 promoter at
sequence position −322 relative to the transcriptional
start site (dsP21-322) was used to activate p21 expres-
sion. A 21-nt dsRNA lacking significant homology to all
known human sequences (dsControl) was used as a non-
specific control. The sequences of these dsRNAs are as
follows: dsP21-322-S, 5’-CCA ACU CAU UCU CCA
AGU A[dT][dT]-3’; dsP21-322-AS, 5’-UAC UUG GAG
AAU GAG UUG G[dT][dT]-3’; dsControl-S, 5’-ACU
ACU GAG UGA CAG UAG A[dT][dT]-3’; and dsControl-
AS, 5’-UCU ACU GUC ACU CAG UAG U[dT][dT]-3’.
Synthetic dsRNAs (including fluorescently labeled dsRNAs)
were manufactured by Ribobio Inc. (Guangzhou, China).
Human p53 siRNAs were purchased from Santa Cruz
Biotechnology (sc-29435; Santa Cruz).
Plasmids and antibodies
The dsP21-322 target site in the p21 promoter constructs
(-395/-197) was PCR amplified using genomic DNA and
verified by sequencing. The PCR fragment was cloned into
the pGL3-Basic luciferase reporter vector upstream of the
firefly luciferase gene to generate the pGL3-promoter
p21 construct. Oligonucleotide sequences are listed in
Additional file 1: Table S1. The following antibodies
were used: monoclonal anti-AGO2 [ab57113, chroma-
tin immunoprecipitation (ChIP) grade, for IP; Abcam];
monoclonal anti-AGO1(2A7) [015–22411, chromatin
immunoprecipitation (ChIP) grade, for IP; Wako]; mono-
clonal anti-biotin (sc-53179, for IP; Santa Cruz); normal
mouse IgG (12–371, for IP; Millipore); monoclonal anti-
RNA polymerase II (05–623, for IP; Millipore); polyclonal
anti-trimethyl-histone H3 (Lys4) (07–473, for IP; Millipore);
polyclonal anti-p21(ab7960, for WB; Abcam); monoclonal
anti-p53(DO-1) (sc-126, for WB; Santa Cruz); and mono-
clonal anti-GAPDH (ab9484, for WB; Abcam).
Cell culture and transfection
All of the cell lines were from ATCC. PC-3, U2-OS,
HeLa, 293T, SaOS2 and 5637 cell lines were maintained
in RPMI medium 1640, and T-24, ACHN, NCI-H1299
and Hep3B cell lines were cultured in Dulbecco’s Modi-
fied Eagle’s Medium that was supplemented with 10 %
FBS, 2 mM L-glutamine, penicillin (100 units/ml), and
streptomycin (100 μg/ml) in a humidified atmosphere of
5 % CO2 maintained at 37 °C. MDA-MB-157 was cul-
tured in L-15 media at 37 °C without CO2. The day be-
fore transfection, the cells were plated in 6-well plates or
150 mm culture dishes (Costar) without antibiotics at a
density of 30–40 %. Transfections of all of the DNA or
RNA duplexes were performed using Lipofectamine 2000
(Invitrogen) or Entranster-R (Engreen) transfection re-
agent according to the manufacturer’s recommendations.
Fluorescence microscopy
Synthesized, fluorescently labeled dsRNA molecules were
transfected into PC-3 cells. The cells were imaged using
converted fluorescence microscopy 24 h or 48 h after
transfection. Cultured cells were washed twice with PBS
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containing the RNase inhibitor RNasin (50 units/ml
final) before each observation to reduce non-specific
background interference. For densitometry analysis, the
relative fluorescence intensity in the nucleus was mea-
sured using Image J software (http://rsbweb.nih.gov/ij).
Luciferase reporter assay
PC-3 and T-24 cells were seeded in 96-well plates, and
p21 promoter-pGL3 constructs were co-transfected with
dsP21-322 or dsControl (50 nM). The activities of firefly
luciferase and Renilla luciferase were measured 48 h
post-transfection using a Dual-Luciferase Reporter Assay
Kit (Promega) following the manufacturer’s protocol.
Firefly luciferase activity was normalized to that of Renilla
luciferase for each sample.
Nucleic acid extraction and RNA analysis
Total cellular RNAs were isolated using TRIzol reagent
(Invitrogen). Expression of the p21 and p53 promoters
was evaluated using RT-qPCR. Each RNA sample was
treated with RNase-free DNase I (Qiagen) to remove any
potential contaminating DNA. Samples of total RNA
(2 μg) were used for cDNA synthesis using SuperScript
reverse transcriptase (Invitrogen) and oligo (dT) primers
or random primers. qPCR was performed to quantify gene
expression using Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen) and the Stratagene Mx3000™ sequence
detection system (Stratagene). The qPCR-specific primer
sequences are listed in Additional file 1: Table S1.
Western blotting
Cultured cells were washed twice with cold PBS contain-
ing a protease inhibitor cocktail (1 μl/ml final). Cellular ly-
sates were prepared by incubating the cells in lysis buffer
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.5 % NP-40
and 2 mM EDTA) containing the protease inhibitor cock-
tail in DEPC-treated water for 30 min at 4 °C, which was
followed by centrifugation at 14,000 g for 15 min at 4 °C.
The protein concentration of the lysates was determined
in the supernatant fraction using a BCA protein assay
kit according to the manufacturer’s protocol (Pierce,
Rockford, IL). For Western blot analysis, the cell lysates
were resolved using 10 % SDS-PAGE gels and transferred
onto nitrocellulose membranes (Millipore). Membranes
were incubated with the appropriate antibodies for 1 h at
room temperature or overnight at 4 °C followed by incu-
bation with a secondary antibody. Immunoreactive bands
were visualized using Luminol Reagent (Santa Cruz) ac-
cording to the manufacturer’s recommendation.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assays were performed using a ChIP assay kit
(17–371; Millipore) according to the manufacturer’s
instructions. A total of 3.5 × 106 cells was used for each
immunoprecipitation. The following antibodies were used
for the immunoprecipitations: anti–Biotin, anti-AGO1,
anti-AGO2, anti-RNA polymerase II, anti-H3k4m3 and
normal mouse IgG. A total of 5 μg of each of the appro-
priate antibodies was used for each ChIP. Immunopre-
cipitated DNA was reverse cross-linked, purified, and
analyzed using qPCR. Primers used for ChIP are described
in Additional file 1: Table S1.
Statistical analysis
Results are expressed as the means ± S.D. Statistical ana-
lyses were performed using SPSS 15.0 statistical software
(SPSS, Chicago, IL, USA). Student’s t-test and one-way
ANOVA followed by Dunnett’s multiple comparison tests
were adopted. Differences were considered statistically sig-
nificant at P < 0.05.
Results
A dsRNA targets the p21 promoter and induces gene
expression
A dsRNA targeting the p21 promoter at position-322
relative to the transcription start site (dsP21-322) was
used to activate p21 expression as previously described
[19] (Fig. 1a). A dsRNA (dsP21-322) and a nonspecific
control dsRNA (dsControl) were transfected into PC-3
(prostate adenocarcinoma) cells, T24 (bladder cancer)
cells and ACHN (renal carcinoma) cells. The expres-
sion levels of p21 were evaluated 72 h or 96 h later
using quantitative real-time PCR (RT-qPCR) and im-
munoblotting. As shown in Fig. 1b and c, dsP21-322
significantly increased p21 mRNA and protein levels
compared with mock and dsControl transfections in
the aforementioned urologic tumor cells. We further
examined the activity of dsP21-322 in four additional
human cell lines, including the human osteosarcoma
cell line U2-OS, the human cervical carcinoma cell line
HeLa, the human hepatoma cell line Hep3B, and the
embryonic kidney cell line 293T. At 72 h, dsP21–322
transfection resulted in varying degrees of p21 induction
in each cell line. Compared with mock transfections, p21
induction was 4.12-, 5.03-, 3.77- and 3.97-fold higher in
U2-OS, HeLa, Hep3B and 293Tcells, respectively (Fig. 1d).
Induction of p21 was further confirmed using Western
blot analysis (Fig. 1e), and the elevated levels of p21 pro-
tein strongly correlated with the increase in p21 mRNA in
all four human cell lines. These data indicate that
saRNA-mediated activation of p21 expression in hu-
man cell lines is a common phenomenon.
Moment analysis of the kinetics of dsRNA subcellular
distribution and RNAa-mediated induction of p21 gene
expression
To monitor the subcellular location of the dsRNA, we
synthesized fluorescently labeled dsRNA molecules derived
Wu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:145 Page 3 of 11
from dsP21-322 or dsControl that were covalently
linked to Cy3 either at the 5’-end of the sense (dsP21-
322-S-5’Cy3 and Control-S-5’Cy3) or the antisense (dsP21-
322-AS-5’Cy3 and Control-AS-5’Cy3) sequence (Fig. 2a).
Twenty-four hours after the transfection of PC-3 cells
with labeled dsRNAs, the cells were imaged using con-
verted fluorescence microscopy to observe the delivery of
dsP21-322 or dsControl into the cytoplasm (Fig. 2b and d).
Fig. 1 dsRNAs targeting the p21 gene promoter induce p21 expression in different human cell lines. Cells were transfected with 50 nM dsRNA
for 72 h. The mRNA and protein levels were analyzed using RT-qPCR and Western blotting, respectively. a A schematic representation of the p21
promoter with its transcriptional start site and the dsRNA target. b p21 and 18S rRNA expression levels were assessed using RT-qPCR in PC-3, T-24, and
ACHN cells after dsP21-322, dsControl, or mock transfections. The p21 expression level was normalized to that of 18S rRNA and plotted as fold change
relative to the mock treatment. The results are expressed as the mean ± S.D. of three independent experiments. c The induction of p21 protein
expression was confirmed by Western blot analysis in PC-3, T-24, and ACHN cells. GAPDH levels were also detected and served as a loading
control. d p21 mRNA expression was analyzed using RT-qPCR, and the results were normalized to 18S RNA in U2-OS, HeLa, Hep3B, and 293T cells after
dsP21-322, dsControl, or mock transfections. The results are expressed as the mean ± S.D. for three independent experiments. e Western blot analysis
of p21 and GAPDH after dsP21-322, dsControl, or mock transfections in U2-OS, HeLa, Hep3B, and 293T cells
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However, most of the dsRNAs actively migrated into
the nucleus from the cytoplasm 48 h after transfection
(Fig. 2b and d). For densitometry analysis, the relative
fluorescence intensity in the nucleus was measured using
Image J software (http://rsbweb.nih.gov/ij). The smaller the
ratio of the IntDen/Area, the greater the intensity of fluor-
escence. The results previously mentioned are showed in
Fig. 2c and e. To further investigate the rate of p21
gene induction using saRNA, we transfected PC-3 or
T-24 cells with dsP21-322 and monitored the cells
throughout a 72 h time course. As shown in Fig. 2f, the
induction of p21 gene expression in both cell lines was
detectable 48 h after transfection, and the levels contin-
ued to rise until 72 h post-transfection, indicating that
saRNA-mediated p21 induction occurs in the nucleus.
We also found that the RNAa activity of fluorescently
modified dsP21-322 (dsP21-322-S-5’Cy3) resulted in a
significant induction of p21 mRNA expression, whereas
dsP21-322-AS-5’Cy3 completely prevented this RNAa
activity despite nuclear localization (Fig. 2g). These re-
sults demonstrated that the saRNA migrated into the
nucleus and successfully entered the RNAa pathway to
mediate sequence-specific activation 48 h after saRNA
transfection.
p53 is not required for dsP21-322-induced p21
expression
To investigate whether p53, a transcriptional activator, is
required for the dsP21-322-mediated activation of p21,
we selected three different p53-null human cell lines,
including the human osteosarcoma cell line SaOS2, the
human breast cancer cell line MDA-MB-157 and the
human non-small cell lung cancer cell line NCI-H1299,
to examine the activity of dsP21-322. Seventy-two hours
after dsP21-322 transfection, we observed a similar acti-
vation effect of the saRNA on p21 mRNA and protein
expression in all of the cell lines, except for NCI-H1299
(Fig. 3a and b). We next performed a loss-of-function
Fig. 2 Moment analysis of the kinetics of dsRNA subcellular distribution and RNAa activity. a Schematic representation of modified dsRNAs (dsP21-322
or dsControl) that were covalently linked to Cy3 at the 5’-end of either the sense (dsRNA-S-5’Cy3) or antisense (dsRNA-AS-5’Cy3) sequences. The sense
strand of each duplex is shown in black, and the antisense strand is shown in red. b PC-3 cells were transfected with 50 nM of fluorescently labeled
dsRNAs for 24 h or c 48 h to monitor the dsRNA subcellular distribution. d PC-3 and T-24 cells were transfected with 50 nM dsP21-322 for the indicated
lengths of time to monitor target gene induction via RNAa. Expression levels of p21 were assessed using RT-qPCR. 18S RNA was also evaluated and
served as a loading control. The results are expressed as the mean ± S.D. of three independent experiments. e p21 and 18S rRNA expression levels
were assessed using RT-qPCR in PC-3 and T-24 cells after dsRNA or mock transfections. The p21 expression level was normalized to that of 18S rRNA
and plotted as the fold change relative to the mock treatment. The results are expressed as the mean ± S.D. of three independent experiments
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study for p53. We transfected U2-OS cells (p53 wild type)
and the human bladder cancer cell line 5637 (p53 mutant)
with siRNAs targeting p53 in combination with dsP21-
322. The effect of reduced p53 expression on the activity
of dsP21-322 was evaluated using RT-qPCR and immuno-
blotting after 72 h and 96 h, respectively. As shown in
Fig. 3c, the inhibition of p53 expression did not prevent
p21 induction by dsP21-322 in both cell lines. We also
observed similar dsP21-322-mediated elevation of p21
protein expression after p53 knockdown in U2-OS cells
(Fig. 3d), suggesting that p53 is not a component of the
dsP21-322-induced p21 expression effector complex.
dsP21-322-mediated p21 expression occurs at the
transcriptional level
To determine whether dsP21-322-mediated p21 expres-
sion occurs at the transcriptional level, we designed a
primer set to introduce an intron in the p21 pre-mRNA,
which can be used to determine whether gene modulation
occurs before or after splicing and to amplify the corre-
sponding RNA species. As shown in Fig. 4a, the addition
of dsP21-322 to PC-3 and T-24 cells increased the levels
of p21 protein-encoding mRNA. We also observed in-
creased levels of the p21 intron, suggesting that RNA
modulation occurs before splicing. Moreover, the addition
of dsP21-322 enhanced the association of RNA Pol II with
the dsP21-322-targeted p21 promoter (Fig. 4c) and the
p21 transcriptional start site (Fig. 4d) in T-24 and U2-OS
cells, indicating that RNA activation occurs at the tran-
scriptional level. Our previous studies indicated that
promoter-targeted dsP21-322 can directly interact with its
target promoter. To further verify this finding, the p21
promoter encoding the putative dsP21-322 binding site
(dsP21BS) was cloned upstream of the luciferase open
Fig. 3 p53 is not required for dsP21-322-induced p21 expression. a The p21, p53 and 18S rRNA expression levels were assessed using RT-qPCR in
Saos2, MDA-MB-157 and NCI-H1299 cells after dsP21-322, dsControl, or mock transfections. The p21 and p53 expression levels were normalized to
that of 18S rRNA and plotted as fold change relative to the mock treatment. The results are expressed as the mean ± S.D. of three independent
experiments. b Induction of p21 and p53 protein expression was confirmed using Western blot analysis in Saos2, MDA-MB-157 and NCI-H1299
cells. GAPDH levels were also detected and served as a loading control. c U2-OS and 5637 cells were transfected with 50 nM control siRNA (siCon)
or dsP21-322. Combination treatments of dsP21-322 and control siRNA or p53-specific siRNA (sip53) were performed with 50 nM of each RNA
duplex. Mock samples were transfected in the absence of dsRNA. Control siRNA consists of scrambled dsRNA based on the p53 siRNA. p21, p53
and 18S rRNA expression levels were assessed using standard RT–qPCR. Data were plotted as the fold change relative to the mock cells. The
results are expressed as the mean ± S.D. of three independent experiments. d p53 and p21 protein expression levels were confirmed using
immunoblot analysis in U2-OS cells. GAPDH levels were also detected and served as a loading control
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reading frame (Fig. 4e). This reporter was co-transfected
into PC-3 or T-24 cells with either dsP21-322 or
dsControl, and a luciferase reporter assay showed that
dsP21-322 can activate the p21 promoter-luciferase re-
porter gene 4 to 5-fold more than the dsControl or a
mock reporter (Fig. 4f). To confirm the specificity of the
identified dsP21-322 binding site in the p21 promoter, we
generated a p21 promoter-luciferase reporter gene with a
nonspecific binding site (NSBS) (Fig. 4e), and dsP21-322
was unable to activate this reporter gene (Fig. 4f). These
results are consistent with previous observations and indi-
cate the specificity of dsP21-322 for the p21 promoter.
dsP21-322-mediated upregulation of p21 correlates with
increased AGO1 and H3K4me3 enrichment at the p21
promoter
AGO1 and AGO2 are involved in several types of dsRNA-
and miRNA-mediated gene regulation, as demonstrated
by both loss-of-function and ChIP analyses [31–33]. Our
previous study revealed that AGO2 enrichment was
Fig. 4 dsP21-322-directed p21 expression occurs at the transcriptional level. a The p21 intron, p21 protein-encoding mRNA and 18S rRNA
expression levels were assessed using RT-qPCR in PC-3 and T-24 cells after dsP21-322, dsControl, or mock transfections. The p21 intron and
p21 protein-encoding mRNA expression levels were normalized to that of 18S rRNA and plotted as the fold change relative to the mock treatment.
b Schematic representation of the locations of the PCR primers that were used in ChIP to amplify the p21 promoter or transcriptional start site.
c A ChIP assay was performed using an anti-RNA Pol II antibody to pull down dsP21-322-targeted promoters or d the p21 transcriptional start
site associated with RNA Pol II in T-24 and U2-OS cells. The resulting DNA was amplified using qPCR and normalized to input levels. e Schematic
representation showing the dsP21-322 binding site (dsP21BS) on the p21 promoter and the nonspecific binding site (NSBS) luciferase reporter.
f A luciferase reporter assay for p21 in PC-3 and T-24 cells transfected with the indicated dsP21-322 and luciferase reporter genes. The input
consists of nuclear extract prior to treatment with the antibody. IgG serves as the negative control antibody. The results are expressed as the
mean ± S.D. calculated from triplicate independent transfection experiments with triplicate qPCR measurements for each
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evident at the dsP21-322 target site after transfection of
dsP21-322 using a ChIP assay in PC-3 cells. We also
observed a similar recruitment of AGO2 at the p21
promoter in the T-24 and U2-OS cell lines (Additional
file 2: Figure S1). In this study, we performed additional
ChIP scanning to examine the association of AGO1 and
a transcriptional activation chromatin marker, H3K4me3,
at the p21 promoter in PC-3 and U2-OS cells after dsP21-
322 transfection using specific antibodies. Four primer
pairs encompassing selected regions across 1.5 kb of the
p21 promoter were designed to amplify DNA that was
pulled down by the corresponding proteins (Fig. 5a). We
quantitatively demonstrated the enrichment of AGO1 and
H3K4me3 at the selected regions using qPCR. As shown
in Fig. 5b-e, compared with the dsControl, the addition of
dsP21-322 increased H3K4me3 enrichment, and a slight
enhancement of AGO1 recruitment at the dsP21-322 tar-
get site (Fig. 5d) and the p21 transcriptional start site
(Fig. 5e) was observed in both cell lines. To further study
the role of AGO1 in the process of RNAa, a dsP21-322-
mutant was synthesized and transfected into PC-3 cells.
The ChIP results demonstrated that mutant dsP21-322
abolished AGO1 recruitment to the dsP21-322 binding
site or the TSS region (Additional file 3: Figure S2). These
results indicate that AGO protein and histone modifi-
cation play important roles in the activation of saRNA-
mediated p21 expression.
Discussion
Recently, RNAa has been shown to activate genes that
are capable of suppressing tumor cell growth (p21, E-
cadherin, p53 and NKX3.1), triggering angiogenesis
Fig. 5 Enrichment of AGO1 and H3K4me3 at dsP21-322-targeted promoters or the p21 transcription start site (TSS). a Schematic representation of
the locations of the PCR primers used for scanning ChIP analysis of 1.5 kb of the proximal p21 promoter. The locations are shown relative to the
TSS. A ChIP assay was performed using an anti-AGO1 or anti-H3K4me3 antibody to pull down the p21 promoter upstream relative to the TSS
(b and c), dsP21-322-targeted promoters d or p21 TSS-associated with AGO1 or H3K4me3 e in PC-3 and T-24 cells. The resulting DNA was
amplified using qPCR and normalized to input levels. The input consists of nuclear extract prior to treatment with the antibody. IgG serves as
the negative control antibody. The results are expressed as the mean ± S.D. calculated from triplicate independent transfection experiments
with triplicate qPCR measurements for each
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(VEGF), influencing stem cell maintenance (KLF4 and
OCT4) and regulating endocrine or metabolism levels (PR
and LDLR) [10, 12–14, 17, 21]. RNAa appears to be a
widespread phenomenon that is conserved in mammals.
Moreover, new findings from a series of recent studies in
mice [34] and Caenorhabditis elegans [35, 36] have re-
vealed an activating role for the small RNA-Argonaute
pathway and established that RNAa is an endogenous
regulatory mechanism of gene expression.
Understanding the mechanism upregulating gene ex-
pression by promoter-targeted saRNAs will require the
identification of the molecular targets of these saRNAs,
their associated key factors, and their epigenetic influ-
ence at complementary genomic loci. Data from this
study using a luciferase reporter assay revealed that
saRNAs associate specifically with intended targets on
the p21 promoter. In combination with the results of
our previous study [19], chromatin immunoprecipita-
tion of biotinylated sense or antisense strands of the
saRNA duplex demonstrated a physical interaction with
the complementary DNA of the p21 promoter, suggest-
ing that promoter sequences are the likely targets of
saRNAs. To support our finding, a report by Place et al.
indicated that the concurrent induction of E-cadherin
and CSDC2 by endogenous miR-373 was specific to the
near-perfect complementarity of the microRNA target
sites in both gene promoters [11]. Similarly, Huang V.
et al. also showed that Ccnb1-activating miRNAs activate
Ccnb1 expression by binding to the Ccnb1 promoter in
an AGO1-dependent manner [37]. In contrast to our
results, studies by Schwartz et al. and Yue et al. ob-
served no direct interaction between saRNAs and chro-
matin in a PR activation model and suggested that
nascent overlapping transcripts of the PR promoter
likely serve as the molecular targets of saRNAs [22, 38].
Although genomic studies have revealed that both sense
and antisense transcripts commonly overlap in promoters
and provide a wide selection of possible targets for saRNAs
[39, 40], we did not detect any non-coding transcripts
overlapping with the p21 promoter [19], which suggests
that the specific target site for different saRNAs may differ
for different genes examined. Thus, any general mecha-
nisms of RNAa would be difficult to establish.
The posttranscriptional gene silencing mediated by
siRNAs is observable within 6 h, with levels maximally
decreasing in ~24 h [41], whereas the rate of gene acti-
vation by saRNAs is typically 24–48 h [10, 42]. These
kinetic differences between classical RNAi and RNAa
suggest that a complex mechanism with additional rate-
limiting steps may play a critical role. In our study,
Figs. 2b, d and 4a show that RNA activation occurs at
the transcriptional level and that this process occurs in
the nucleus. Acquiring access to the nucleus may be an
additional rate-limiting step. In addition, a classic histone
modification marker of active transcription, H3K4me3,
was recruited to the p21 promoter following induction
by dsP21-322 (Fig. 5), suggesting that changes in chro-
matin structure further contribute to the slower kinetics of
RNAa. The fact that the saRNA transfection maintained
gene induction for nearly 2 weeks (~12 days) also supports
this notion [42]. Other studies by Janowski [12] and Huang
[37] also reported that H3K4me3 is enriched at the PR and
cyclin B1 promoters following induction by their respective
saRNAs. Intriguingly, the specific histone changes that
occur following saRNA treatment differ for the various
genes and cell types examined. For example, a reduction in
H3K9 acetylation (H3acK9) was associated with saRNA
induction of PR [12], but no significant changes occurred
at the p21 promoter after transfection with dsP21-322
[19]. Moreover, saRNAs targeting PAWR, PR, and inter-
leukin (IL)-24 promoters have all been shown to increase
dimethylated H3K4 (H3K4me2) [12, 15, 43]. However,
the enrichment of H3K4me2 was not observed at either
the E-cadherin or IL-32 gene promoters after saRNA
treatments [10, 43].
AGO1 and AGO2 proteins are expressed in both the
cytoplasm and nucleus and are well-characterized in
mammals, assisting in post-transcriptional gene silencing
(PTGS) [44, 45] and transcriptional gene silencing (TGS)
[46, 47]. Moreover, AGO2 is involved in several types of
dsRNA-mediated gene activation [10, 12, 37], as revealed
with the RNA immunoprecipitation of the AGO2 protein,
which showed association with hundreds of sites in
transcriptionally active regions. Additionally, AGO2 was
bound to small RNAs enriched in the promoter regions of
many genes [48, 49]. However, the expression of AGO1
was not necessary for efficient gene activation, and AGO1
was not recruited to the target promoter or the non-
coding transcript for gene activation in previous studies
[31, 42]. In our report, we showed that the induction of
p21 by saRNA correlates with increased AGO1 enrich-
ment at the p21 promoter, which suggests that AGO1 also
participates in activation at the transcriptional level. This
finding was also supported by a recent study that sug-
gested that nuclear AGO1 is pervasively associated with
the promoters of actively transcribed genes that are in-
volved in growth, survival, and cell cycle progression and
selectively interacts with RNA polymerase II in human
cancer cells [32]. Taken together, AGO1and AGO2 pro-
teins localize to the nucleus and interact with a number of
RNA molecules and protein factors, including chromatin,
RNA polymerase II and epigenetic markers to induce
gene activation.
Though AGO1 could not lead apparent expression
change of p21 gene in the process of RNAa, AGO1 may
have something to do with the control of constitutive
and alternative splicing in human cancer cells [50]. Add-
itionally, AGO proteins participated in many biological
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processes, not only in classical AGO-mediated gene-
silencing principles, which could affect mRNA transla-
tion and decay, but also in regulating gene transcription
and repairing damaged DNA double-strands [45]. To
sum up, we hypothesized that AGO1should probably
have something to do with the function chromatin modifi-
cation of AGO proteins to a certain extent, such as the
histone methylation and acetylation. Even the modifica-
tion of AGO proteins themselves, such as phosphorylation
and ubiquitin [45], could occur in that process. However,
there are still major gaps in our understanding of AGO1
function at the molecular level in the process of dsP21-
322-mediated p21 activation. In the future, we will
continue to elucidate the mechanism of AGO1 func-
tion in RNAa.
Knockdown of the p53 transcript by siRNAs did not
prevent the significant up regulation of p21 transcription,
revealing the specificity of p21 gene activation mediated
by saRNA. As such, we demonstrated that saRNAs ac-
tively migrate into the nucleus and recruit AGO protein
to complementary elements within the p21 promoter.
Chromatin DNA-saRNA interactions act as scaffolds
for transcription factor recruitment and trigger histone
modification, which may be a general mechanism for
saRNA-controlled p21 gene expression.
Conclusions
In summary, the meager evidence currently available
makes it difficult to understand the general mechanisms
of RNAa, particularly the target molecules of saRNAs.
Our findings distinctly revealed the saRNA-mediated
mechanistic and functional aspects of tumor suppressor
gene p21 activation, which may offer a novel approach
for gene therapies. The ability to selectively upregulate
TSG expression against a disease state can have a far-
reaching impact on basic research and the development
of cancer therapeutics.
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